Ruifen Sun

Dr. Ruifen Sun


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LZLu Zhang
Lu Zhang
SLSongyu Liu
Songyu Liu
KDKai Ding
Kai Ding
BZBin Zeng
Bin Zeng
BLBo Li
Bo Li
RSRuifen Sun
Ruifen Sun

30 August 2024 in Phytomedicine
Verified
Journal Article
Closed access
SLSongyu Liu
Songyu Liu
LZLu Zhang
Lu Zhang
KDKai Ding
Kai Ding
BZBin Zeng
Bin Zeng
BLBo Li
Bo Li
XSXiaosan Su
Xiaosan Su

1 January 2025 in Engineered Science
Verified
Journal Article
Open access
PDF file
HMHaoxin Ma
Haoxin Ma
XDXiaowei Dai
Xiaowei Dai
TWTao Wang
Tao Wang
ZHZhongmei He
Zhongmei He
RDRui Du
Rui Du
KZKui Zhao
Kui Zhao
This article identifies targets of uridine for anti-aging through network pharmacology molecular docking, and further confirmed through cell models.

26 December 2025 in Phytomedicine
Verified
Journal Article
Closed access
SNShu-Man Ni
Shu-Man Ni
XLXiao-Yue Li
Xiao-Yue Li
SCSi-Jun Chen
Si-Jun Chen
ARAn-Lv Ren
An-Lv Ren
LYLu Yang
Lu Yang
XSXiaosan Su
Xiaosan Su

28 May 2025 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YWYu-Tong Wang
Yu-Tong Wang
QLQuan-Yang Liao
Quan-Yang Liao
YDYun-Zhu Dong
Yun-Zhu Dong
YSYue Shu
Yue Shu
XLXiao-Yue Li
Xiao-Yue Li
XSXiaosan Su
Xiaosan Su

13 May 2025 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ZLZheng-Rui Li
Zheng-Rui Li
YWYu-Feng Wang
Yu-Feng Wang
CZChen- Rong Zuo
Chen- Rong Zuo
JMJing-Sheng Men
Jing-Sheng Men
XLXin-Yuan Li
Xin-Yuan Li
RSRuifen Sun
Ruifen Sun
This meta-analysis systematically evaluated the effectiveness and safety of immune checkpoint inhibitors (ICIs) in treating advanced cervical cancer, emphasizing their potential as transformative therapeutic options in this complex clinical landscape. EMBASE, Web of Science, PubMed, and the Cochrane Library were thoroughly searched for articles on the outcomes of ICIs in advanced cervical cancer patients. A pooled analysis was performed to evaluate the objective response rate (ORR: reported as an odds ratio (OR), progression-free survival (PFS; hazard ratio (HR), overall survival (OS; HR), and safety outcomes risk ratio (RR). Subgroup and sensitivity analyses were also conducted to identify potential sources of bias and heterogeneity. Our meta-analysis included 5 studies involving 3,112 patients. Compared with standard therapies, treatment with immune checkpoint inhibitors (ICIs) significantly improved the objective response rate (ORR; OR = 1.68, 95% CI = 1.27–2.23), prolonged progression-free survival (PFS; HR = 0.72, 95% CI = 0.65–0.80), and extended overall survival (OS; HR = 0.69, 95% CI = 0.61–0.79). Subgroup analyses revealed potential predictors of treatment response. Moreover, ICIs exhibit a manageable safety profile, with adverse events consistent with known immune-related toxicities. This meta-analysis highlights the promising efficacy and favourable safety profile of immune checkpoint inhibitors in advanced cervical cancer. These findings suggest a paradigm shift in treatment strategies, with ICIs emerging as a potential cornerstone therapy. Further research is warranted to elucidate optimal patient selection, combination therapies, and long-term outcomes. This study provides valuable insights for clinicians and researchers, paving the way for personalized and effective treatment approaches for advanced cervical cancer.